Detection of EGFR- and HER2-activating mutations in squamous cell carcinoma involving the head and neck
- 1 January 2006
- journal article
- research article
- Published by Elsevier in Laboratory Investigation
- Vol. 19 (5), 634-640
- https://doi.org/10.1038/modpathol.3800552
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Selecting Patients for Epidermal Growth Factor Receptor Inhibitor Treatment: A FISH Story or a Tale of Mutations?Journal of Clinical Oncology, 2005
- Phase I Study of Gefitinib Plus Celecoxib in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckJournal of Clinical Oncology, 2005
- Current Knowledge and Future Directions of the Selective Epidermal Growth Factor Receptor Inhibitors Erlotinib (Tarceva®) and Gefitinib (Iressa®)The Oncologist, 2005
- The role of cetuximab in the treatment of squamous cell cancer of the head and neckExpert Opinion on Biological Therapy, 2005
- Treatment with gefitinib (ZD 1839) in a patient with advanced cutaneous squamous cell carcinomaBritish Journal of Dermatology, 2005
- BRAF mutation in thyroid cancerEndocrine-Related Cancer, 2005
- Medical treatment in head and neck cancerAnnals of Oncology, 2005
- Epidermal Growth Factor Receptor Mutations, Small-Molecule Kinase Inhibitors, and Non–Small-Cell Lung Cancer: Current Knowledge and Future DirectionsJournal of Clinical Oncology, 2005
- Switching on kinases: oncogenic activation of BRAF and the PDGFR familyNature Reviews Cancer, 2004
- Detection of c-kit–Activating Mutations in Gastrointestinal Stromal Tumors by High-Resolution Amplicon Melting AnalysisAmerican Journal of Clinical Pathology, 2004